Artiva Biotherapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
4.0%projected annual EPS growth
Analyst Coverage
5analysts covering
FY EPS (est.)
-$2.43next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 12 Nov 2026 |
Monitoring Framework
Key Performance Indicators
AlloNK Phase 3 Registrational Trial Initiation in Refractory Rheumatoid Arthritis (RA) AnnuallyTarget: Initiation of Phase 3 randomized controlled trial evaluating AlloNK plus rituximab versus rituximab alone in approximately 150 refractory RA patients
AlloNK Clinical Efficacy (ACR50 Response Rate at 6 Months in Refractory RA) Quarterly7,100.0%Target: Sustained high ACR50 response rate at 6 months in the Phase 3 registrational trial
Cash Runway (Years of Funding) QuarterlyTarget: Funding operations into Q2 2027 (prior to the May 2026 $300M capital raise)
Watch Items
- Phase 3 Registrational Trial Initiation for AlloNK in Refractory RATrigger: Second Half of 2026 (H2 2026)Action: Monitor official press releases and clinical trial registries (ClinicalTrials.gov) for first patient dosed in the Phase 3 trial.
- Safety and Tolerability Profile of AlloNK in Outpatient SettingsTrigger: Any occurrence of severe Cytokine Release Syndrome (CRS) or Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)Action: Review safety updates from ongoing basket trials and the upcoming Phase 3 trial to ensure outpatient viability remains intact.
- Primary Efficacy Data Readout for Phase 3 Refractory RA TrialTrigger: Second Half of 2028 (H2 2028)Action: Track clinical progress and prepare for major data release ahead of the planned BLA submission in 2029.
Research as of 19 Jun 2026